Coegin introduces new tailor-made Follicopeptide complementary product - launching early 2026

Coegin Pharma AB ("Coegin" or "the Company") announces that it has finalized the development of a new, tailor-made Follicopeptide complementary product. It is designed to strengthen existing hair, enhance the performance of Follicopeptide and improve the overall user experience. The new add-on product is expected to reach the market no later than March 2026, marking another strategic step in the commercial expansion of the Follicopeptide ecosystem.

Designed to accelerate visible results and strengthen commercial potential
The new product is formulated to strengthen the existing hair, revitalize the scalp, increase the receptiveness to Follicopeptide and thereby improve the overall user experience.

By adding a complementary product to the Follicopeptide ecosystem, Coegin further strengthens the commercial platform around Follicopeptide, offering new opportunities for increased profitability across the entire distribution chain.

Jens Eriksson, CEO of Coegin Pharma, comments:
"This new complementary product is a smart and natural extension of our Follicopeptide product portfolio. It enhances the user experience and provides early visible results - something both customers and partners value highly. From a business perspective, it also allows us and our distribution partners to increase margins and build long-term brand loyalty. We have received positive feedback from both existing and potential new partners, who see clear commercial potential in this new addition."

Positive partner feedback and early commercial interest 
The product concept has already been presented to Coegin's existing launch partners as well as potential new distributors, all of whom have expressed enthusiasm for the opportunity to expand their offerings.

Dr. John Zibert, Chief Medical Officer at Coegin Pharma, comments: 
"This product gives us a unique opportunity to further optimize the Follicopeptide experience. By strengthening existing hair and improving scalp receptiveness, we can enhance the effects of Follicopeptide. This is supported by human clinical safety data demonstrating excellent skin compatibility. This new product is an elegant way to create early satisfaction for users while strengthening long-term outcomes."

For further information, please contact:
Jens Eriksson, CEO, Coegin Pharma AB
Email: [email protected]

About Coegin Pharma
Coegin Pharma is a Swedish biotech company with cutting-edge innovations for hair and skin. The company is currently commercializing its patented hair growth innovation Follicopeptide® on a global scale. In development is NPP-4, a next-generation peptide that represents a novel approach to regulating skin pigmentation through advanced biotechnology.

Coegin Pharma's share is listed on NGM Nordic SME and dual-listed on Börse Stuttgart. The company is headquartered in Lund, Sweden.

More information - including subscription to company updates and links to social media - is available at coeginpharma.com